Answers are grounded in this paper and cite their sources.
Review analyzes the effectiveness of CRFR1 antagonists on alcohol craving in alcohol use disorder, suggesting implications for future research.
Corticotropin releasing factor (CRF) is a neuropeptide that plays a key role in behavioral and physiological responses to stress. A large body of animal literature implicates CRF acting at type 1 CRF receptors (CRFR1) in consumption by alcohol-dependent subjects, stress-induced reinstatement of alcohol seeking, and possibly binge alcohol consumption. These studies have encouraged recent pilot studies of CRFR1 antagonists in humans with alcohol use disorder (AUD). It was a great disappointment to many in the field that these studies failed to show an effect of these compounds on stress-induced alcohol craving. Here, we examine these studies to explore potential limitations and discuss preclinical and human literature to ask whether CRFR1 is still a valid drug target to pursue for the treatment of AUD.
No takes yet. Share an insight, caveat, or question.
Pomrenze et al. (2017) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: